RT @Stiddyo: #OP0228 Phase 3 RCT on Risankizumab - KEEPsAKE 2 -PsA with 49% prior bDMARD 95% prior csDMARD: week 24 resu
Tweet Content
#OP0228 Phase 3 RCT on Risankizumab - KEEPsAKE 2 -PsA with 49% prior bDMARD 95% prior csDMARD: week 24 results
PE: ACR20 51% active vs 26% on PLC
PASI90: 55% active vs. 10% PLC
#EULAR2021 @RheumNow https://t.co/UkZLcXTNnq
Show on Archive Page
On
Display in Search Results
On
PDQ
Off